Skip to main content

Table 3 Secondary endpoint: 28-day survival rate

From: An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome

AT activity (%) Survival
pAT AT gamma
% (n/N) % (n/N)
< 50 76.7 (33/43) 85.4 (35/41)
50–70 78.3 (54/69) 89.7 (61/68)
Total [95% CI] 77.7 (87/112) [68.8–85.0] 87.3 (96/110) [79.6–92.9]
Adjusted a [95% CI] 77.7 [70.7–84.7] 88.1 [81.1–95.0]
  1. AT antithrombin, CI confidence interval, pAT plasma-derived antithrombin
  2. aThe protocol was amended to include all patients with AT activity ≤ 70% so that the patient population would more accurately reflect the intended clinical use. The (adjusted) survival rate and its 95% CI were calculated for each treatment group after stratification using the Woolson–Bean method, stratified by the AT activity (< 50%, 50–70%) at study enrollment